Monograph
A10BH02 - Vildagliptin |
Propably not porphyrinogenic |
PNP |
Rationale
Vildagliptin is not a CYP substrate and has no capacity for inhibition or induction of the major CYP-subclasses. There are no pharmacokinetic drug interactions with vildagliptin as perpetrator.
Chemical description
Hydroxy admantan amino acetyl pyrrolidine carbonitrile
Therapeutic characteristics
Vildagliptin is indicated for the improvement of glycaemic control in adult patients with type 2 diabetes mellitus. It can be used as mono therapy or as part of combination therapy with other anti-diabetic drugs.
Vildagliptin increases the levels of endogenous incretin hormones via potent and selective inhibition of dipeptidyldipeptidase-4 (DPP-4). Nausea is a common side effect of vildagliptin that may potentially be porphyrinogenic through reduction in carbohydrate intake.
Metabolism and pharmacokinetics
Vildagliptin is not a CYP substrate; it is metabolized by hydrolysis mainly in the kidneys. It is devoid of capacities for induction or inhibition of any of the CYP-subclasses. There are no pharmacokinetic interactions with vildagliptin as perpetrator.
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
Golightly LK, Drayna CC, et al. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14. |
|
| 2. | Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL. Clin Pharmacokinet. 2012 Mar 1;51(3):147-62. |
22339447 |
| 3. | Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ. Diabetes Obes Metab. 2010 Aug; 12(8):648-58. |
20590741 |
| * | Summary of Product Characteristics | |
| 4. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Galvus.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024